GlassScriptPhysician profile
Brenden David Connor
NPI 1902241441
$586.62
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $59.38 · 2021: $248 · 2022: $12.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $188.66 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $142.46 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $96.68 | 2019-2021 | |
| Vifor Pharma, INC. | $42.10 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $26.03 | 2021 | |
| Horizon Therapeutics Plc | $24.00 | 2019 | |
| Glaxosmithkline, LLC. | $17.94 | 2021 | |
| Fresenius USA Marketing, INC. | $15.18 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.81 | 2021 | |
| Medtronic, INC. | $12.25 | 2022 | |
| Akebia Therapeutics INC | $8.51 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenden Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.